Filing Details
- Accession Number:
- 0000950170-25-083410
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-06-06 21:03:02
- Reporting Period:
- 2025-06-04
- Filing Date:
- 2025-06-06
- Accepted Time:
- 2025-06-06 21:03:02
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1808865 | Iteos Therapeutics Inc. | ITOS | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1457477 | David Hallal | C/O Iteos Therapeutics, Inc. 321 Arsenal Street Watertown MA 02472 | No | No | No | No |
Transaction Summary
| Sold: | 114,682 shares | Avg. Price: $10.15 | Total Value: $1,164,404.66 |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-06-04 | 38,227 | $4.30 | 38,227 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-06-04 | 38,227 | $10.07 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2025-06-05 | 38,227 | $4.30 | 38,227 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-06-05 | 38,227 | $10.15 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2025-06-06 | 38,228 | $4.30 | 38,228 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-06-06 | 38,228 | $10.24 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2025-06-04 | 38,227 | $0.00 | 38,227 | $4.30 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2025-06-05 | 38,227 | $0.00 | 38,227 | $4.30 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2025-06-06 | 38,228 | $0.00 | 38,228 | $4.30 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 76,455 | 2022-07-01 | 2025-06-11 | No | 4 | M | Direct |
| 38,228 | 2022-07-01 | 2025-06-11 | No | 4 | M | Direct |
| 0 | 2022-07-01 | 2025-06-11 | No | 4 | M | Direct |
Footnotes
- The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2025
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.01 to $10.16, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.09 to $10.22, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.19 to $10.29, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Billionaire Hedge Funds
